Colorectal Cancer

During the 2017 ESMO Congress, to be held September 8-12 in Madrid, Spain, the European Society for Medical Oncology (ESMO) will award 4 oncologists with its distinguished annual awards:

In a 17-0 vote, the FDA’s Oncologic Drugs Advisory Committee unanimously recommended the approval of ABP-215, a biosimilar for bevacizumab.

Luis A. Diaz Jr, MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.

A large analysis of data comparing selective internal radiotherapy (SIRT) plus chemotherapy to chemotherapy did not show expected improvements in survival, but an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.

Overall survival was prolonged with treatment with ziv-aflibercept compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated <em>RAS, KRAS,</em> and <em>BRAF</em> genes.

Panitumumab has been approved by the FDA in combination with FOLFOX as a frontline treatment for patients with <em>RAS</em> wild-type metastatic colorectal cancer.

Psychological intervention can substantially lower fear of cancer recurrence (FCR) in survivors, improving their quality of life, anxiety, and cancer-specific distress.

Luis A. Diaz Jr., MD, head, Division of Solid Tumor Oncology, discusses pembrolizumab (Keytruda) therapy for microsatellite instability-high colorectal cancer and other tumor types.

Drug manufacturer XBiotech has cancelled the phase III XCITE study of MABp1 (Hutruo; formerly Xilonix) in patients with advanced colorectal cancer, following a second prospectively planned, unblinded analysis.

Surgically Unresectable Metastatic Colorectal Cancer

Surgically Unresectable Metastatic Colorectal Cancer

Case Presentation in Advanced Colon Cancer

Case Presentation in Advanced Colon Cancer